United Therapeutics Corporation Stock-Based Compensation
United Therapeutics Corporation (UTHR) reported Stock-Based Compensation of $77.30 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-05
- United Therapeutics Corporation share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $43.40M, a 14.81% increase year-over-year.
- United Therapeutics Corporation share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $33.90M, a 6.60% increase year-over-year.
- United Therapeutics Corporation share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $39.00M, a 44.44% increase year-over-year.
- United Therapeutics Corporation share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $39.10M, a 6.24% decline year-over-year.
- United Therapeutics Corporation share-based payment arrangement, noncash expense for fiscal 2025 was $147.70M, a 2.57% increase from fiscal 2024.
- United Therapeutics Corporation share-based payment arrangement, noncash expense for fiscal 2024 was $144.00M, a 268.29% increase from fiscal 2023.
- United Therapeutics Corporation share-based payment arrangement, noncash expense for fiscal 2023 was $39.10M, a 63.39% decline from fiscal 2022.
- United Therapeutics Corporation share-based payment arrangement, noncash expense for fiscal 2022 was $106.80M, a 22.89% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 3 month as first filed | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 6 month as first filed | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 9 month as first filed | Share-based Payment Arrangement, Noncash Expense 12 month | Share-based Payment Arrangement, Noncash Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $43.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $77.30M 10-Q · filed 2026-08-05 | $116.30M derived: sum of 3 quarters · filed 2026-08-05 | $155.40M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $33.90M 10-Q · filed 2026-05-06 | $72.90M derived: sum of 2 quarters · filed 2026-05-06 | $112.00M derived: sum of 3 quarters · filed 2026-05-06 | $149.80M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $39.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $78.10M derived: sum of 2 quarters · filed 2026-02-25 | $115.90M derived: sum of 3 quarters · filed 2026-08-05 | $147.70M 10-K · filed 2026-02-25 | ||||
| 2025-09-30 | $39.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $76.90M derived: sum of 2 quarters · filed 2026-08-05 | $108.70M 10-Q · filed 2025-10-29 | $135.70M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $37.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $69.60M 10-Q · filed 2026-08-05 | $96.60M derived: sum of 3 quarters · filed 2026-08-05 | $138.30M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $31.80M 10-Q · filed 2026-05-06 | $58.80M derived: sum of 2 quarters · filed 2026-05-06 | $100.50M derived: sum of 3 quarters · filed 2026-05-06 | $150.20M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $27.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $68.70M derived: sum of 2 quarters · filed 2026-02-25 | $118.40M derived: sum of 3 quarters · filed 2026-02-25 | $144.00M 10-K · filed 2026-02-25 | ||||
| 2024-09-30 | $41.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $91.40M derived: sum of 2 quarters · filed 2025-10-29 | $117.00M 10-Q · filed 2025-10-29 | $133.60M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-06-30 | $49.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $75.30M 10-Q · filed 2025-07-30 | $91.90M derived: sum of 3 quarters · filed 2026-02-25 | $113.00M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-03-31 | $25.60M 10-Q · filed 2025-04-30 | $42.20M derived: sum of 2 quarters · filed 2026-02-25 | $63.30M derived: sum of 3 quarters · filed 2026-02-25 | $77.10M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2023-12-31 | $16.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $37.70M derived: sum of 2 quarters · filed 2026-02-25 | $51.50M derived: sum of 3 quarters · filed 2026-02-25 | $39.10M 10-K · filed 2026-02-25 | ||||
| 2023-09-30 | $21.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $34.90M derived: sum of 2 quarters · filed 2024-10-30 | $22.50M 10-Q · filed 2024-10-30 | $87.30M derived: sum of 4 quarters · filed 2025-02-26 | ||||
| 2023-06-30 | $13.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | $1.40M 10-Q · filed 2024-07-31 | $66.20M derived: sum of 3 quarters · filed 2025-02-26 | $63.80M derived: sum of 4 quarters · filed 2025-02-26 | ||||
| 2023-03-31 | -$12.40M 10-Q · filed 2024-05-01 | $52.40M derived: sum of 2 quarters · filed 2025-02-26 | $50.00M derived: sum of 3 quarters · filed 2025-02-26 | $115.50M derived: sum of 4 quarters · filed 2025-02-26 | ||||
| 2022-12-31 | $64.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $62.40M derived: sum of 2 quarters · filed 2025-02-26 | $127.90M derived: sum of 3 quarters · filed 2025-02-26 | $106.80M 10-K · filed 2025-02-26 | ||||
| 2022-09-30 | -$2.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $63.10M derived: sum of 2 quarters · filed 2023-11-01 | $42.00M 10-Q · filed 2023-11-01 | $86.70M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2022-06-30 | $65.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $44.40M 10-Q · filed 2023-08-02 | $89.10M derived: sum of 3 quarters · filed 2024-02-21 | $113.70M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2022-03-31 | -$21.10M 10-Q · filed 2023-05-03 | $23.60M derived: sum of 2 quarters · filed 2024-02-21 | $48.20M derived: sum of 3 quarters · filed 2024-02-21 | $77.30M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2021-12-31 | $44.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $69.30M derived: sum of 2 quarters · filed 2024-02-21 | $98.40M derived: sum of 3 quarters · filed 2024-02-21 | $138.50M 10-K · filed 2024-02-21 | ||||
| 2021-09-30 | $24.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $53.70M derived: sum of 2 quarters · filed 2022-11-02 | $93.80M 10-Q · filed 2022-11-02 | $187.50M derived: sum of 4 quarters · filed 2023-02-22 | ||||
| 2021-06-30 | $29.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $69.20M 10-Q · filed 2022-08-03 | $162.90M derived: sum of 3 quarters · filed 2023-02-22 | $150.40M derived: sum of 4 quarters · filed 2023-02-22 | ||||
| 2021-03-31 | $40.10M 10-Q · filed 2022-05-04 | $133.80M derived: sum of 2 quarters · filed 2023-02-22 | $121.30M derived: sum of 3 quarters · filed 2023-02-22 | $173.10M derived: sum of 4 quarters · filed 2023-02-22 | ||||
| 2020-12-31 | $93.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $81.20M derived: sum of 2 quarters · filed 2023-02-22 | $133.00M derived: sum of 3 quarters · filed 2023-02-22 | $163.80M 10-K · filed 2023-02-22 | ||||
| 2020-09-30 | -$12.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $39.30M derived: sum of 2 quarters · filed 2021-11-03 | $70.10M 10-Q · filed 2021-11-03 | $99.60M derived: sum of 4 quarters · filed 2022-02-24 | ||||
| 2020-06-30 | $51.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $82.60M 10-Q · filed 2021-08-04 | $112.10M derived: sum of 3 quarters · filed 2022-02-24 | $136.00M derived: sum of 4 quarters · filed 2022-02-24 | ||||
| 2020-03-31 | $30.80M 10-Q · filed 2021-05-05 | $60.30M derived: sum of 2 quarters · filed 2022-02-24 | $84.20M derived: sum of 3 quarters · filed 2022-02-24 | $47.00M derived: sum of 4 quarters · filed 2022-02-24 | ||||
| 2019-12-31 | $29.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $53.40M derived: sum of 2 quarters · filed 2022-02-24 | $16.20M derived: sum of 3 quarters · filed 2022-02-24 | $45.40M 10-K · filed 2022-02-24 | ||||
| 2019-09-30 | $23.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28 | -$13.30M derived: sum of 2 quarters · filed 2020-10-28 | $15.90M 10-Q · filed 2020-10-28 | $18.70M derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2019-06-30 | -$37.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-29 | -$8.00M 10-Q · filed 2020-07-29 | -$5.20M derived: sum of 3 quarters · filed 2021-02-24 | $46.20M derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2019-03-31 | $29.20M 10-Q · filed 2020-04-29 | $32.00M derived: sum of 2 quarters · filed 2021-02-24 | $83.40M derived: sum of 3 quarters · filed 2021-02-24 | $103.90M derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2018-12-31 | $2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $54.20M derived: sum of 2 quarters · filed 2021-02-24 | $74.70M derived: sum of 3 quarters · filed 2021-02-24 | -$26.40M 10-K · filed 2021-02-24 | ||||
| 2018-09-30 | $51.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $71.90M derived: sum of 2 quarters · filed 2019-10-30 | -$29.20M 10-Q · filed 2019-10-30 | $89.30M derived: sum of 4 quarters · filed 2020-02-26 | ||||
| 2018-06-30 | $20.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | -$80.60M 10-Q · filed 2019-07-31 | $37.90M derived: sum of 3 quarters · filed 2020-02-26 | $13.90M derived: sum of 4 quarters · filed 2020-02-26 | ||||
| 2018-03-31 | -$101.10M 10-Q · filed 2019-05-01 | $17.40M derived: sum of 2 quarters · filed 2020-02-26 | -$6.60M derived: sum of 3 quarters · filed 2020-02-26 | -$8.50M derived: sum of 4 quarters · filed 2020-02-26 | ||||
| 2017-12-31 | $118.50M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $94.50M derived: sum of 2 quarters · filed 2020-02-26 | $92.60M derived: sum of 3 quarters · filed 2020-02-26 | $73.50M 10-K · filed 2020-02-26 | ||||
| 2017-09-30 | -$24.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | -$25.90M derived: sum of 2 quarters · filed 2018-10-31 | -$45.00M 10-Q · filed 2018-10-31 | $60.30M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-06-30 | -$1.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | -$21.00M 10-Q · filed 2018-08-01 | $84.30M derived: sum of 3 quarters · filed 2019-02-27 | $134.20M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-03-31 | -$19.10M 10-Q · filed 2018-05-02 | $86.20M derived: sum of 2 quarters · filed 2019-02-27 | $136.10M derived: sum of 3 quarters · filed 2019-02-27 | $137.60M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2016-12-31 | $105.30M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $155.20M derived: sum of 2 quarters · filed 2019-02-27 | $156.70M derived: sum of 3 quarters · filed 2019-02-27 | $12.10M 10-K · filed 2019-02-27 | ||||
| 2016-09-30 | $49.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-25 | $51.40M derived: sum of 2 quarters · filed 2017-10-25 | -$93.20M 10-Q · filed 2017-10-25 | $24.20M derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2016-06-30 | $1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-27 | -$143.10M 10-Q · filed 2017-07-27 | -$25.70M derived: sum of 3 quarters · filed 2018-02-21 | -$144.60M derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2016-03-31 | -$144.60M 10-Q · filed 2017-04-26 | -$27.20M derived: sum of 2 quarters · filed 2018-02-21 | -$146.10M derived: sum of 3 quarters · filed 2018-02-21 | -$98.80M derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2015-12-31 | $117.40M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-21 | -$1.50M derived: sum of 2 quarters · filed 2018-02-21 | $45.80M derived: sum of 3 quarters · filed 2018-02-21 | $280.30M 10-K · filed 2018-02-21 | $280.25M 10-K · filed 2016-02-25 | |||
| 2015-09-30 | -$118.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-27 | -$71.60M derived: sum of 2 quarters · filed 2016-10-27 | $162.90M 10-Q · filed 2016-10-27 | $162.89M 10-Q · filed 2015-10-27 | $195.27M derived: sum of 4 quarters · filed 2017-02-22 | |||
| 2015-06-30 | $47.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-28 | $281.80M 10-Q · filed 2016-07-28 | $281.81M 10-Q · filed 2015-07-28 | $314.17M derived: sum of 3 quarters · filed 2017-02-22 | $534.50M derived: sum of 4 quarters · filed 2017-02-22 | |||
| 2015-03-31 | $234.50M 10-Q · filed 2016-04-28 | $234.53M 10-Q · filed 2015-04-28 | $266.87M derived: sum of 2 quarters · filed 2017-02-22 | $487.20M derived: sum of 3 quarters · filed 2017-02-22 | $485.32M derived: sum of 4 quarters · filed 2017-02-22 | |||
| 2014-12-31 | $32.37M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-22 | $252.70M derived: sum of 2 quarters · filed 2017-02-22 | $250.82M derived: sum of 3 quarters · filed 2017-02-22 | $190.10M 10-K · filed 2017-02-22 | $190.05M 10-K · filed 2015-02-24 | |||
| 2014-09-30 | $220.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-27 | $218.45M derived: sum of 2 quarters · filed 2015-10-27 | $157.73M 10-Q · filed 2015-10-27 | $335.93M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-06-30 | -$1.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-29 | -$62.60M 10-Q · filed 2014-07-29 | $115.61M derived: sum of 3 quarters · filed 2016-02-25 | $189.99M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-03-31 | -$60.72M 10-Q · filed 2015-04-28 | $117.48M derived: sum of 2 quarters · filed 2016-02-25 | $191.86M derived: sum of 3 quarters · filed 2016-02-25 | $224.85M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2013-12-31 | $178.20M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $252.59M derived: sum of 2 quarters · filed 2016-02-25 | $285.57M derived: sum of 3 quarters · filed 2016-02-25 | $320.79M 10-K · filed 2016-02-25 | ||||
| 2013-09-30 | $74.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-28 | $107.37M derived: sum of 2 quarters · filed 2014-10-28 | $142.58M 10-Q · filed 2014-10-28 | $132.13M derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2013-06-30 | $32.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-29 | $68.20M 10-Q · filed 2014-07-29 | $57.75M derived: sum of 3 quarters · filed 2015-02-24 | $88.89M derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2013-03-31 | $35.21M 10-Q · filed 2014-04-29 | $24.76M derived: sum of 2 quarters · filed 2015-02-24 | $55.91M derived: sum of 3 quarters · filed 2015-02-24 | $65.35M derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2012-12-31 | -$10.45M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $20.69M derived: sum of 2 quarters · filed 2015-02-24 | $30.14M derived: sum of 3 quarters · filed 2015-02-24 | $30.11M 10-K · filed 2015-02-24 | ||||
| 2012-09-30 | $31.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-29 | $40.59M derived: sum of 2 quarters · filed 2013-10-29 | $40.57M 10-Q · filed 2013-10-29 | $62.64M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2012-06-30 | $9.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-25 | $9.42M 10-Q · filed 2013-07-25 | $31.50M derived: sum of 3 quarters · filed 2014-02-25 | -$16.11M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2012-03-31 | -$24.00K 10-Q · filed 2013-04-25 | $22.05M derived: sum of 2 quarters · filed 2014-02-25 | -$25.56M derived: sum of 3 quarters · filed 2014-02-25 | -$52.59M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2011-12-31 | $22.07M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | -$25.53M derived: sum of 2 quarters · filed 2014-02-25 | -$52.57M derived: sum of 3 quarters · filed 2014-02-25 | -$15.71M 10-K · filed 2014-02-25 | ||||
| 2011-09-30 | -$47.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01 | -$74.65M derived: sum of 2 quarters · filed 2012-11-01 | -$37.79M 10-Q · filed 2012-11-01 | $15.03M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2011-06-30 | -$27.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-26 | $9.82M 10-Q · filed 2012-07-26 | $62.63M derived: sum of 3 quarters · filed 2013-02-26 | $94.01M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2011-03-31 | $36.86M 10-Q · filed 2012-04-26 | $89.67M derived: sum of 2 quarters · filed 2013-02-26 | $121.04M derived: sum of 3 quarters · filed 2013-02-26 | $120.67M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2010-12-31 | $52.81M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $84.19M derived: sum of 2 quarters · filed 2013-02-26 | $83.82M derived: sum of 3 quarters · filed 2013-02-26 | $113.94M 10-K · filed 2013-02-26 | ||||
| 2010-09-30 | $31.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | $31.00M derived: sum of 2 quarters · filed 2011-10-27 | $61.13M 10-Q · filed 2011-10-27 | $88.43M derived: sum of 4 quarters · filed 2012-02-28 | ||||
| 2010-06-30 | -$370.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-28 | $29.75M 10-Q · filed 2011-07-28 | $57.06M derived: sum of 3 quarters · filed 2012-02-28 | $82.35M derived: sum of 4 quarters · filed 2012-02-28 | ||||
| 2010-03-31 | $30.13M 10-Q · filed 2011-04-28 | $57.43M derived: sum of 2 quarters · filed 2012-02-28 | $82.72M derived: sum of 3 quarters · filed 2012-02-28 | |||||
| 2009-12-31 | $27.30M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-28 | $52.59M derived: sum of 2 quarters · filed 2012-02-28 | $101.02M 10-K · filed 2012-02-28 | |||||
| 2009-09-30 | $25.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-28 | $73.71M 10-Q · filed 2010-10-28 | ||||||
| 2009-06-30 | $48.42M 10-Q · filed 2010-07-28 | |||||||
| 2008-12-31 | $28.70M 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |